Published in Int J Epidemiol on November 03, 2010
Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One (2012) 2.41
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 1.73
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med (2015) 1.61
Transitioning HIV care and treatment programs in southern Africa to full local management. AIDS (2012) 1.47
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS Biol (2016) 1.43
High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa. PLoS One (2011) 1.33
Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis (2015) 1.31
HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav (2012) 1.26
HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One (2012) 1.23
Collecting maternal health information from HIV-positive pregnant women using mobile phone-assisted face-to-face interviews in Southern Africa. J Med Internet Res (2013) 1.22
Women and HIV in Sub-Saharan Africa. AIDS Res Ther (2013) 1.20
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol (2011) 1.13
The HIV-1 epidemic: low- to middle-income countries. Cold Spring Harb Perspect Med (2012) 1.12
HIV incidence among non-pregnant women living in selected rural, semi-rural and urban areas in KwaZulu-Natal, South Africa. AIDS Behav (2012) 1.10
Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr (2013) 1.09
Pregnant women living with HIV (WLH) supported at clinics by peer WLH: a cluster randomized controlled trial. AIDS Behav (2014) 1.05
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials (2011) 1.04
Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest? J Acquir Immune Defic Syndr (2014) 1.03
Incidence of pregnancy after initiation of antiretroviral therapy in South Africa: a retrospective clinical cohort analysis. Infect Dis Obstet Gynecol (2012) 1.02
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One (2013) 0.99
Detection of antenatal depression in rural HIV-affected populations with short and ultrashort versions of the Edinburgh Postnatal Depression Scale (EPDS). Arch Womens Ment Health (2013) 0.98
HPTN 068: A Randomized Control Trial of a Conditional Cash Transfer to Reduce HIV Infection in Young Women in South Africa-Study Design and Baseline Results. AIDS Behav (2016) 0.94
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J Acquir Immune Defic Syndr (2015) 0.93
The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. Lancet Glob Health (2016) 0.92
Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. Sex Transm Infect (2014) 0.89
Inclusion of adolescent girls in HIV prevention research - an imperative for an AIDS-free generation. J Int AIDS Soc (2014) 0.89
The biobehavioral Women's Health CoOp in Pretoria, South Africa: study protocol for a cluster-randomized design. BMC Public Health (2014) 0.87
Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis (2014) 0.87
HIV incidence and prevalence among cohorts of women with higher risk behaviour in Bloemfontein and Rustenburg, South Africa: a prospective study. BMJ Open (2012) 0.86
HIV Incidence and Spatial Clustering in a Rural Area of Southern Mozambique. PLoS One (2015) 0.86
Representation of women and pregnant women in HIV research: a limited systematic review. PLoS One (2013) 0.85
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS Behav (2015) 0.85
Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. BMC Public Health (2015) 0.85
Trends in HIV Prevalence in Pregnant Women in Rural South Africa. J Acquir Immune Defic Syndr (2015) 0.84
Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition. AIDS (2013) 0.83
The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis. PLoS One (2015) 0.81
Impact of elevated maternal HIV viral load at delivery on T-cell populations in HIV exposed uninfected infants in Mozambique. BMC Infect Dis (2015) 0.81
Changing spatial patterns and increasing rurality of HIV prevalence in the Democratic Republic of the Congo between 2007 and 2013. Health Place (2016) 0.79
Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa. Contraception (2014) 0.79
Southern Africa: the Highest Priority Region for HIV Prevention and Care Interventions. Curr HIV/AIDS Rep (2015) 0.79
Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa. Clin Infect Dis (2016) 0.78
HIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventions. AIDS Behav (2015) 0.78
The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials. PLoS One (2012) 0.77
Antibodies for HIV prevention in young women. Curr Opin HIV AIDS (2015) 0.77
Diagnosis and Disclosure of HIV Status: Implications for Women's Risk of Physical Partner Violence in the Postpartum Period. J Acquir Immune Defic Syndr (2016) 0.76
The need for multipurpose prevention technologies in sub-Saharan Africa. BJOG (2014) 0.76
Adjusting HIV prevalence estimates for non-participation: an application to demographic surveillance. J Int AIDS Soc (2015) 0.76
High Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South Africa. PLoS One (2016) 0.76
Individual and Population Level Impact of Key HIV Risk Factors on HIV Incidence Rates in Durban, South Africa. PLoS One (2016) 0.75
Passive Suicidal Ideation and Community Mental Health Resources in South Africa. Community Ment Health J (2016) 0.75
"Boring" family routines reduce non-communicable diseases: a commentary and call for action. Arch Public Health (2015) 0.75
Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. BJOG (2014) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
The dynamics of HIV transmission in out of school young heterosexual men in South Africa: a systematic scoping review protocol. Syst Rev (2017) 0.75
Postpartum family planning service provision in Durban, South Africa: client and provider perspectives. Health Care Women Int (2013) 0.75
Rising Levels of HIV Infection in Older Adults in Eastern Zimbabwe. PLoS One (2016) 0.75
Low HIV incidence in pregnant and postpartum women receiving a community-based combination HIV prevention intervention in a high HIV incidence setting in South Africa. PLoS One (2017) 0.75
Incident HIV during pregnancy and early postpartum period: a population-based cohort study in a rural area in KwaZulu-Natal, South Africa. BMC Pregnancy Childbirth (2017) 0.75
How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis. J Int AIDS Soc (2017) 0.75
Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS (2005) 8.71
Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Global perspectives on the sexual and reproductive health of adolescents: patterns, prevention, and potential. Lancet (2007) 4.93
National HIV incidence measures--new insights into the South African epidemic. S Afr Med J (2007) 4.69
"Know your epidemic, know your response": a useful approach, if we get it right. Lancet (2008) 4.24
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One (2008) 3.45
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
"A bit more truthful": the validity of adolescent sexual behaviour data collected in rural northern Tanzania using five methods. Sex Transm Infect (2004) 3.37
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet (2008) 2.75
Estimation of adult antiretroviral treatment coverage in South Africa. S Afr Med J (2009) 2.71
Estimating incidence from prevalence in generalised HIV epidemics: methods and validation. PLoS Med (2008) 2.42
SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One (2007) 2.41
Measuring trends in prevalence and incidence of HIV infection in countries with generalised epidemics. Sex Transm Infect (2006) 2.17
From effectiveness to impact: contraception as an HIV prevention intervention. Sex Transm Infect (2008) 2.09
The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr (2008) 1.91
Pregnancy in effectiveness trials of HIV prevention agents. Sex Transm Dis (2007) 1.79
HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis (2006) 1.75
Sexual and reproductive health for all: a call for action. Lancet (2006) 1.55
Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care (2007) 1.29
Family planning and HIV: strange bedfellows no longer. AIDS (2009) 1.28
Provincial mortality in South Africa, 2000--priority-setting for now and a benchmark for the future. S Afr Med J (2005) 1.17
Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe. Contemp Clin Trials (2009) 1.15
Moving beyond the alphabet soup of HIV prevention. AIDS (2008) 1.14
HIV incidence rates and risk factors for urban women in Zambia: preparing for a microbicide clinical trial. Sex Transm Dis (2009) 1.13
Pregnancy prevention practices among women with multiple partners in an HIV prevention trial. J Acquir Immune Defic Syndr (2007) 1.08
High AIDS-related mortality among young women in rural KwaZulu-Natal. S Afr Med J (2007) 1.06
HIV-1 incidence among women of reproductive age in Malawi. Int J STD AIDS (2008) 1.04
HIV incidence estimates are key to understanding the changing HIV epidemic in South Africa. S Afr Med J (2007) 0.81
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis (2003) 5.09
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Health in South Africa: changes and challenges since 2009. Lancet (2012) 3.44
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 2.70
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med (2012) 2.48
Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis (2012) 2.42
Microbicides & their implications in HIV prevention. Indian J Med Res (2010) 2.36
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 2.29
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol (2011) 2.26
High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med (2010) 2.23
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) (2003) 2.03
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 1.73
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog (2013) 1.65
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr (2003) 1.30
HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav (2012) 1.26
Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. J Infect Dis (2009) 1.21
Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis (2012) 1.17
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol (2013) 1.13
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis (2013) 1.12
The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sex Transm Infect (2011) 1.10
Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women. Clin Infect Dis (2011) 1.09
High prevalence of abnormal Pap smears among young women co-infected with HIV in rural South Africa - implications for cervical cancer screening policies in high HIV prevalence populations. S Afr Med J (2007) 1.09
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav (2014) 1.09
APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS (2010) 1.08
Utilizing nucleic acid amplification to identify acute HIV infection. AIDS (2007) 1.07
Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav (2014) 1.06
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials (2011) 1.04
Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression. J Virol (2010) 1.04
HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health (2012) 1.04
Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr (2006) 1.03
Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol (2010) 1.02
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav (2014) 1.00
Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. J Infect Dis (2009) 1.00
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis (2012) 0.99
The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol (2011) 0.98
Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region. PLoS One (2013) 0.98
Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. AIDS (2011) 0.97
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. AIDS (2012) 0.96
Anaemia in acute HIV-1 subtype C infection. PLoS One (2008) 0.96
Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis (2014) 0.96
Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. J Acquir Immune Defic Syndr (2016) 0.96
Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. J Acquir Immune Defic Syndr (2014) 0.95
When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis (2013) 0.94
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J Acquir Immune Defic Syndr (2015) 0.93
Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. Future Microbiol (2010) 0.93
Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testing. PLoS One (2013) 0.92
Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J Virol (2013) 0.92
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Antiretroviral therapy: challenges and options in South Africa. Lancet (2003) 0.91
HIV prevention in high-risk women in South Africa: condom use and the need for change. PLoS One (2012) 0.91
Evolution of epidemiologic methods and concepts in selected textbooks of the 20th century. Soz Praventivmed (2004) 0.90
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr (2015) 0.90
Extensively drug-resistant tuberculosis in women, KwaZulu-Natal, South Africa. Emerg Infect Dis (2011) 0.89
Incidence of Sexually Transmitted Infections among HIV-positive sex workers in KwaZulu-Natal, South Africa. Sex Transm Dis (2002) 0.89
Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa. BMC Infect Dis (2014) 0.88
Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. Sex Transm Dis (2014) 0.88
Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. Trop Med Int Health (2004) 0.87
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol (2013) 0.87
Single low-dose ceftriaxone for the treatment of gonococcal ophthalmia--implications for the national programme for the syndromic management of sexually transmitted diseases. S Afr Med J (2002) 0.87
The preventive misconception: experiences from CAPRISA 004. AIDS Behav (2014) 0.86
HIV infection in high school students in rural South Africa: role of transmissions among students. AIDS Res Hum Retroviruses (2014) 0.86
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS Behav (2015) 0.85
An AIDS-free generation? Science (2012) 0.85